Oral Masitinib Phase 3 Results Promising for Severe Asthma Oral Masitinib Phase 3 Results Promising for Severe Asthma

The tyrosine kinase inhibitor reduced severe exacerbations by 35%, regardless of eosinophil count, in a population that hasn ' t had an effective oral treatment option, new research shows.Medscape Medical News
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Pulmonary Medicine News Source Type: news